Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial - The Lancet Diabetes & Endocrinology
Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension - ScienceDirect
Osteoporosemedikant Denusomab (Prolia®, XGEVA®) zur Betazellregeneration bei Diabetes? | DGE Blog
Prolia by Amgen gets petitioned for Black Box Warning | Fierce Pharma
iSpatula - The US Food and Drug Administration (FDA) has approved denosumab (Prolia, Amgen) for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture, defined as defined
Osteoporose-Medikament regt Betazellen an - diabetes-news : diabetes-news
Denosumab: Wirkung und Nebenwirkungen
Prolia®: physiologischer Knochenschutz
NICE offers advice on fractures drug | GPonline
Osteoporoseprophylaxe bei endokriner Mammakarzinom-Therapie
Diagnose und Management der Osteoporose bei Diabetes mellitus (Update 2019) | SpringerLink
Osteoporosis Drug May Treat Diabetes
Sequenzielle Therapie im Langzeitmanagement planen – Rosenfluh.ch
Warnung für Prolia und Xgeva | APOTHEKE ADHOC
Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study | The BMJ
PROLIA 60MG/ML FS MIT ANS 1 St (PZN 12346689) - mycare.de
Dr. Reddy Prolia 60 Mg, Packaging Type: Vial
Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial - The Lancet Diabetes & Endocrinology
FDA Alert: 'Substantial' Hypocalcemia Risk with Prolia Use
Diabetes und Osteoporose – Zusammenhänge, Empfehlungen, Ausblick - d-journal
A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients | Scientific Reports